Physician profile
Robert Mario Be
NPI 1417923970
$6,219.45
in general payments reported to CMS, 2019-2025
36 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $937 · 2020: $544 · 2021: $761 · 2022: $1,161 · 2023: $736 · 2024: $858 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,815.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,787.27 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $621.60 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $557.29 | 2019-2025 | Entyvio |
| Celgene Corporation | $502.65 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $464.87 | 2019-2025 | Xifaxan |
| Ardelyx, INC. | $278.17 | 2022-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $209.50 | 2019-2023 | Rebyota |
| Genzyme Corporation | $175.19 | 2024-2025 | |
| Madrigal Pharmaceuticals | $170.33 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $160.06 | 2019-2023 | Injectafer |
| Pfizer INC. | $150.98 | 2019-2025 | |
| Qol Medical, LLC | $100.80 | 2019-2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $98.87 | 2020-2024 | Linzess |
| Gilead Sciences, INC. | $95.24 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $93.34 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $85.39 | 2021-2023 | Talicia |
| Covidien Lp | $77.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $61.30 | 2024-2025 | Dupixent |
| Cumberland Pharmaceuticals, INC. | $59.39 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $52.73 | 2025 | Iqirvo |
| Celltrion USA INC. | $47.29 | 2024 | Vegzelma |
| Mallinckrodt Hospital Products INC. | $44.34 | 2022-2023 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $34.29 | 2024-2025 | Voquezna |
| Allergan, INC. | $33.92 | 2019 | |
| Medtronic, INC. | $32.32 | 2024 | Interstim |
| Nestle Healthcare Nutrition INC. | $31.82 | 2021-2022 | |
| Ucb, INC. | $27.68 | 2019 | |
| Merck Sharp & Dohme LLC | $27.22 | 2022-2023 | Dificid |
| Lilly USA, LLC | $26.95 | 2025 | Omvoh |
| Braintree Laboratories, INC. | $23.82 | 2022 | |
| Olympus America INC. | $19.83 | 2019 | |
| Echosens North America, INC. | $19.82 | 2023 | Fibroscan |
| Romark Laboratories, Lc | $18.08 | 2020 | |
| Pharmacosmos Therapeutics INC. | $18.00 | 2021 | |
| Alnylam Pharmaceuticals INC. | $12.10 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Be listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.